Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epetraborole for Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)
jRCT2071220118Phase 3Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Mycobacterium avium-intracellulare infection (MAI) comparing Epetraborole arm with Placebo arm (2 arms). Primary endpoints: Phase 2 by-subject sputum conversion through Month 6 (Micro-ITT), Phase 2 safety profile of epetraborole 500 mg once daily and 1 more. Started Jun 2023; status: completed.
02
Drugs
epetraborole
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on jRCT2071220118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220118.